NEW YORK, July 3 – The pharmacogenomics market is expected to grow to more than $6 billion by 2005, compared with $1.7 billion in 2000, consulting firm Frost & Sullivan said Tuesday in a report.

The figures for the pharmacogenomics market reflect actual and anticipated revenues stemming from services, gene-based diagnostics, and orphan drugs.

Yet, despite the strong growth outlook, Frost & Sullivan said that ethical debates could put a damper on growth, particularly in diagnostics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.